Rapid AI Progress And Aging Trends Will Fuel Immunotherapy Advancement
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 4 Analysts
Published
08 Jul 25
Updated
23 Jul 25
AnalystHighTarget's Fair Value
US$10.00
85.2% undervalued intrinsic discount23 Jul
US$1.48
1Y
-9.8%7D
-2.0%